PDGFRB and neoplasm: In contrast, combining TAK-779 treatment with PDGFRβ vaccine failed to considerably reduce the extent of tumor and carcinosis development compared to each treatment alone, again supporting the greatest potential of CCL5 inhibition compared to CCR5 antagonism in this CRC model.